Brief: Cantargia Granted Important Us Patent For Nadunolimab
27/08/2025 06:32
Aug 27 (Reuters) - Cantargia AB CANTA.ST: GRANTED IMPORTANT US PATENT FOR NADUNOLIMAB PATENT IS VALID UNTIL 2035 (EXCLUDING ANY PATENT TERM EXTENSION) Source text: ID:nMFN5xrqDl Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML